title: Cell-based therapies for systemic lupus erythematosus.
abstract: Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by multi-organ disorders. The pathogenesis of SLE is complex. Corticosteroids and immunosuppressive drugs are widely used to treat patients with SLE. However, these indiscriminate suppressors of the immune-mediated inflammatory aberration treat SLE at the cost of considerable adverse effects. Undoubtedly, there is a need for safer and more effective treatments for SLE. Cell-based therapies, although very much in their infancy, are of increasing interest in the treatment of SLE due to their potential for long-term suppression or a possible cure of the disease. Several immunoregulatory cell types, including regulatory T cells, mesenchymal stem cells, B-cells and natural killer cells, have recently been developed as novel products for tolerance-promoting therapies. Here, we provide a brief overview of current research of new cell-based therapeutic approaches that have undergone pre-clinical or clinical trials in the treatment of SLE.
authors.forename: Jieyue
authors.initials: J
authors.lastname: Liao
authors.forename: Christopher
authors.initials: C
authors.lastname: Chang
authors.forename: Haijing
authors.initials: H
authors.lastname: Wu
authors.forename: Qianjin
authors.initials: Q
authors.lastname: Lu
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D015551:Autoimmunity; D001402:B-Lymphocytes / Q000166:cytology; D064987:Cell- and Tissue-Based Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy*; D045164:Mesenchymal Stem Cell Transplantation
chemical_list: D000305:Adrenal Cortex Hormones; D005938:Glucocorticoids; D007155:Immunologic Factors